Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value.

Open Forum Infect Dis 2018 Mar 7;5(3):ofy031. Epub 2018 Feb 7.

University of Washington School of Pharmacy, Seattle, Washington.

Respiratory syncytial virus (RSV) infection is the most common cause of lower respiratory tract infection and the leading cause of hospitalization among young children, incurring high annual costs among US children under the age of 5 years. Palivizumab has been found to be effective in reducing hospitalization and preventing serious lower respiratory tract infections in high-risk infants. This paper presents a systematic review of the cost-effectiveness studies of palivizumab and describes the main highlights of a round table discussion with clinical, payer, economic, research method, and other experts. The objectives of the discussion were to (1) review the current state of clinical, epidemiology, and economic data related to severe RSV disease; (2) review new cost-effectiveness estimates of RSV immunoprophylaxis in US preterm infants, including a review of the field's areas of agreement and disagreement; and (3) identify needs for further research.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofy031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833316PMC
March 2018
23 Reads

Publication Analysis

Top Keywords

respiratory tract
8
lower respiratory
8
review cost-effectiveness
8
respiratory syncytial
8
syncytial virus
8
round table
4
method experts
4
highlights round
4
main highlights
4
table discussion
4
economic method
4
payer economic
4
describes main
4
discussion clinical
4
clinical payer
4
cost-effectiveness studies
4
infections high-risk
4
high-risk infants
4
tract infections
4
serious lower
4

Similar Publications